Benjamin Wooden
Icahn School of Medicine at Mount Sinai
12 Papers
30 Citations
Benjamin Wooden is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Complement system. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
TL;DR: Recent advances in the fields of computational and systems biology are reviewed and opportunities for researchers to use big data sets in the field of gastroenterology and hepatology to complement traditional means of diagnostic and therapeutic discovery are highlighted.
63
Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.
Daniel F. Hicks,Nicolas Goossens,Nicolas Goossens,Ana Blas-Garcia,Ana Blas-Garcia,Takuma Tsuchida,Takuma Tsuchida,Benjamin Wooden,Michael C. Wallace,Michael C. Wallace,Natalia Nieto,Abigale Lade,Benjamin Redhead,Arthur I. Cederbaum,Joel T. Dudley,Bryan C. Fuchs,Youngmin A. Lee,Yujin Hoshida,Scott L. Friedman +18 more
TL;DR: C1QTNF2 expression is reduced during hepatic stellate cell activation in culture and in a mouse model of alcoholic liver injury in vivo, and its expression correlates with better clinical outcomes in patients with hepatitis C Cirrhosis, suggesting it may have a protective role in cirrhosis progression.
33
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
Yask Gupta,David J. Friedman,Michelle McNulty,Atlas Khan,Brandon Lane,Chen Wang,Juntao Ke,Gina Y. Jin,Benjamin Wooden,Andrea L Knob,Tze Y Lim,Gerald B. Appel,Kinsie Huggins,Lili Liu,Adele Mitrotti,Megan Chryst Stangl,Andrew S. Bomback,Rik Westland,Monica Bodria,Maddalena Marasa,Ning Shang,David J Cohen,R. John Crew,William Morello,Pietro A. Canetta,Jai Radhakrishnan,Jeremiah Martino,Qingxue Liu,Wendy K. Chung,Angelica Espinoza,Yuan Luo,Wei Wei,QiPing Feng,Chunhua Weng,Yilu Fang,Iftikhar J. Kullo,Mohammadreza Naderian,Nita A. Limdi,Marguerite R. Irvin,Hemant K Tiwari,Sumit Mohan,Maya Rao,Geoffrey K. Dube,Ninad S. Chaudhary,Orlando M Gutierrez,Suzanne E. Judd,Mary Cushman,Leslie A. Lange,Ethan M Lange,Daniel L. Bivona,Miguel Verbitsky,Cheryl Winkler,J. B. Kopp,Dominick Santoriello,Ibrahim Batal,Sérgio Veloso Brant Pinheiro,Eduardo Araújo Oliveira,A. C. Simões e Silva,Isabella Pisani,Enrico Fiaccadori,Fangming Lin,L. Gesualdo,Antonio Amoroso,Gian Marco Ghiggeri,Vivette D. D’Agati,Riccardo Magistroni,Eimear E. Kenny,Ruth J F Loos,Giovanni Montini,Friedhelm Hildebrandt,Dirk S Paul,S. Petrovski,David B. Goldstein,Matthias Kretzler,Rasheed Gbadegesin,Ali G. Gharavi,Krzysztof Kiryluk,Matthew G. Sampson,Martin R. Pollak,Simone Sanna-Cherchi +79 more
TL;DR: It is shown that the presence of the AP OL1 p.N264K missense variant, when co-inherited with the G2 APOL1 risk allele, substantially reduces the penetrance of the G1G2 and G2G2 high-risk genotypes by rendering these genotypes low-risk.
23
Complement inhibitors for kidney disease.
Benjamin Wooden,M. Navarro-Torres,Andrew S. Bomback +2 more
TL;DR: In this paper , the authors survey the evidence on using complement inhibition from the earliest, small-scale studies focusing on C5-targeting agents to more recent, large, multi-center, randomized trials utilizing complement blockade higher up in the complement pathway at the level of C3.
23
Strong protective effect of the APOL1 p.N264K variant against G2-associated FSGS and kidney disease
Yask Gupta,David S. Friedman,Michelle McNulty,Atlas Khan,Brandon M. Lane,Chen Wang,Juntao Ke,Gina Y. Jin,Benjamin Wooden,Andrea L Knob,Tze Yin Lim,Gerald B. Appel,Kinsie Huggins,Lili Liu,Adele Mitrotti,Megan Chryst Stangl,Andrew S. Bomback,Rik Westland,Monica Bodria,Maddalena Marasa,Ning Shang,David J. Cohen,R. John Crew,William Morello,Pietro A. Canetta,Jai Radhakrishnan,Jeremiah Martino,Qingxue Liu,Wendy K. Chung,Angelica Espinoza,Yunhao Liu,Wei Wei,QiPing Feng,Chunhua Weng,Yilu Fang,Iftikhar J. Kullo,Mohammadreza Naderian,Nita A. Limdi,Marguerite R. Irvin,Hemant K. Tiwari,Sumit Mohan,Maya K. Rao,Geoffrey K. Dube,Ninad S. Chaudhary,Orlando M. Gutiérrez,Suzanne E. Judd,Mary Cushman,Leslie A. Lange,Ethan M. Lange,Daniel L. Bivona,Miguel Verbitsky,Cheryl Winkler,Jeffrey B. Kopp,Dominick Santoriello,Ibrahim Batal,S. Veloso,Brant Pinheiro,Eduardo A. Oliveira,Ana Cristina Simões e Silva,Isabella Pisani,Enrico Fiaccadori,Fangming Lin,Loreto Gesualdo,Antonio Amoroso,Gian Marco Ghiggeri,Vivette D. D'Agati,Riccardo Magistroni,Eimear E. Kenny,R. Loos,Giovanni Montini,Friedhelm Hildebrandt,Dirk S. Paul,Slavé Petrovski,David Goldstein,Matthias Kretzler,Rasheed Gbadegesin,Ali G. Gharavi,Krzysztof Kiryluk,Matthew G. Sampson,Martin R. Pollak,Simone Sanna-Cherchi +80 more
TL;DR: It is shown that the presence of the AP OL1 p.N264K missense variant, when co-inherited with the G2 APOL1 risk allele, substantially reduces the penetrance of the G1G2 and G2G2 high-risk genotypes by rendering these genotypes low-risk.
2